Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
XORTX Therapeutics Inc ( (TSE:XRTX) ) has shared an update.
On April 21, 2026, XORTX Therapeutics Inc. announced it has regained compliance with Nasdaq’s minimum bid price requirement, which mandates a share price of at least US$1.00. The company achieved this after implementing a 1-for-5 reverse stock split on April 6, 2026, leading to its shares trading above US$1.00 for at least 10 consecutive trading days, curing the previous listing deficiency and stabilizing its position on the exchange.
The compliance confirmation, received from Nasdaq on April 20, 2026, helps secure XORTX’s continued access to U.S. capital markets at a time when it is advancing multiple late-stage and preclinical kidney and gout therapies. Maintaining its Nasdaq listing supports liquidity for existing shareholders and underpins future financing options as the company progresses its development programs.
Spark’s Take on XRTX Stock
According to Spark, TipRanks’ AI Analyst, XRTX is a Neutral.
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for gout and progressive kidney disease. Its pipeline includes three clinically advanced programs—XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney and organ injury related to respiratory virus infections—alongside earlier-stage candidates targeting diabetic nephropathy and other rare and prevalent kidney disorders.
Average Trading Volume: 936
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.16M
For a thorough assessment of XRTX stock, go to TipRanks’ Stock Analysis page.